Filing Flows › Alkermes (ALKS) › Q2 2025
Alkermes (ALKS) Q2 2025 earnings results (second quarter 2025)
10-Q filed Jul 29, 2025
Alkermes (ALKS) reported revenue of $391M for the second quarter 2025 (Q2 2025), -2% from a year earlier and +27% from the quarter before. Operating margin was 23.8%, net earnings $87.1M (22.3% of revenue).
Alkermes, Q2 2025: revenue $391M (-2% year over year), operating margin 23.8%, net earnings $87.1M, operating cash flow $150M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $391M | +27% | -2% |
| Operating profit | $93.0M | +574% | -15% |
| Net earnings | $87.1M | +288% | -5% |
| Operating cash flow | $150M | +52% | +3% |
| Free cash flow | $137M | +55% | -1% |
What changed
Revenue was $390.7M in Q2 2025, down 2% year over year and up 27% from the previous quarter. Vivitrol was the largest line at 31% of revenue. Royalty lost $42.7M year over year (down 39%), 504% of the total change.
Operating profit was $93.0M, a 23.8% margin (down 3.7 points year over year). Total costs grew 3% against a revenue fall of 2%. The fastest-growing cost line was Research & development (+30%). Net earnings were $87.1M, down 5% year over year. The effective tax rate was 16.9%.
Operating cash flow was $150.2M (up 3% year over year), 172% of net earnings. Non-cash charges added back $7.8M of depreciation and amortization and $25.0M of share-based compensation. Working capital and other items added $30.3M. Capital expenditures of $13.0M left free cash flow of $137.2M.
Questions
What was Alkermes' revenue in the second quarter 2025?
Alkermes (ALKS) reported revenue of $391M for the second quarter 2025 (Q2 2025), -2% from a year earlier and +27% from the quarter before.
Was Alkermes profitable in the second quarter 2025?
Operating profit was $93.0M (23.8% of revenue) and net earnings $87.1M.
Source: Alkermes 10-Q on SEC EDGAR.